NCT02222558View on ClinicalTrials.gov

Oral Testosterone for the Treatment of Hypogonadism in Males

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

May 31, 2015

Conditions
Hypogonadism
Interventions
DRUG

TSX-002

TSX-002 are capsules with testosterone as the active ingredient.

Trial Locations (1)

92120

San Diego Sexual Medicine, San Diego

All Listed Sponsors
lead

TesoRx Pharma, LLC

INDUSTRY

NCT02222558 - Oral Testosterone for the Treatment of Hypogonadism in Males | Biotech Hunter | Biotech Hunter